Clinical trial

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

NCT04743622

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-04-30

PhasePHASE4

Study timeline

Study start (actual)2019-04-30Date precision: day

Registry last updated2021-02-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Glaucomaunresolved

Ocular Hypertensionunresolved

Interventions

MonoprostDRUG

XalatanDRUG · verified · RxNorm: Xalatan

Sponsors & collaborators

CHA Universitylead sponsor

Samil Pharmaceutical Co., Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04743622 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.